Literature DB >> 35725377

Early donepezil monotherapy or combination with metoprolol significantly prevents subsequent chronic heart failure in rats with reperfused myocardial infarction.

Meihua Li1, Can Zheng2, Toru Kawada2, Kazunori Uemura2, Masashi Inagaki2, Keita Saku2, Masaru Sugimachi2.   

Abstract

Despite the presence of clinical guidelines recommending that β-blocker treatment be initiated early after reperfused myocardial infarction (RMI), acute myocardial infarction remains a leading cause of chronic heart failure (CHF). In this study, we compared the effects of donepezil, metoprolol, and their combination on the progression of cardiac remodeling in rats with RMI. The animals were randomly assigned to untreated (UT), donepezil-treated (DT), metoprolol-treated (MT), and a combination of donepezil and metoprolol (DMT) groups. On day 8 after surgery, compared to the UT, the DT and DMT significantly improved myocardial salvage, owing to the suppression of macrophage infiltration and apoptosis. After the 10-week treatment, the DT and DMT exhibited decreased heart rate, reduced myocardial infarct size, attenuated cardiac dysfunction, and decreased plasma levels of brain natriuretic peptide and catecholamine, thereby preventing subsequent CHF. These results suggest that donepezil monotherapy or combined therapy with β-blocker may be an alternative pharmacotherapy post-RMI.
© 2022. The Author(s).

Entities:  

Keywords:  Chronic heart failure; Donepezil; Infarct size; Metoprolol; Myocardial salvage; Reperfused myocardial infarction

Mesh:

Substances:

Year:  2022        PMID: 35725377     DOI: 10.1186/s12576-022-00836-2

Source DB:  PubMed          Journal:  J Physiol Sci        ISSN: 1880-6546            Impact factor:   2.781


  54 in total

Review 1.  Myocardial reperfusion injury.

Authors:  Derek M Yellon; Derek J Hausenloy
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

2.  Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials.

Authors:  Gregg W Stone; Harry P Selker; Holger Thiele; Manesh R Patel; James E Udelson; E Magnus Ohman; Akiko Maehara; Ingo Eitel; Christopher B Granger; Paul L Jenkins; Melissa Nichols; Ori Ben-Yehuda
Journal:  J Am Coll Cardiol       Date:  2016-04-12       Impact factor: 24.094

3.  Percutaneous left main coronary disease treatment without on-site surgery back-up in patients with acute coronary syndromes: immediate and 2-year outcomes.

Authors:  Andrea Gagnor; Francesco Tomassini; Enrico Romagnoli; Vincenzo Infantino; Maria Cristina Rosa Brusin; Cristina Maria; Rosario Tripodi; Giuseppe Sangiorgi; Ferdinando Varbella
Journal:  Catheter Cardiovasc Interv       Date:  2011-10-05       Impact factor: 2.692

4.  Infarct size reduction by propranolol before and after coronary ligation in dogs.

Authors:  M M Rasmussen; K A Reimer; R A Kloner; R B Jennings
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

5.  Long-term trends in the incidence of heart failure after myocardial infarction.

Authors:  Raghava S Velagaleti; Michael J Pencina; Joanne M Murabito; Thomas J Wang; Nisha I Parikh; Ralph B D'Agostino; Daniel Levy; William B Kannel; Ramachandran S Vasan
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

6.  Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.

Authors:  G Z Feuerstein; T L Yue; H Y Cheng; R R Ruffolo
Journal:  J Hypertens Suppl       Date:  1993-06

7.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský
Journal:  Eur Heart J       Date:  2018-01-07       Impact factor: 29.983

8.  The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion.

Authors:  Borja Ibanez; Giovanni Cimmino; Susanna Prat-González; Gemma Vilahur; Randolph Hutter; Mario J García; Valentin Fuster; Javier Sanz; Lina Badimon; Juan J Badimon
Journal:  Int J Cardiol       Date:  2009-11-12       Impact factor: 4.164

9.  Failure of intravenous metoprolol to limit acute myocardial infarct size in a nonreperfused porcine model.

Authors:  K B Kern; R W Hilwig; A Warner; M Basnight; G A Ewy
Journal:  Am Heart J       Date:  1995-04       Impact factor: 4.749

10.  CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018.

Authors:  Yukio Ozaki; Yuki Katagiri; Yoshinobu Onuma; Tetsuya Amano; Takashi Muramatsu; Ken Kozuma; Satoru Otsuji; Takafumi Ueno; Nobuo Shiode; Kazuya Kawai; Nobuhiro Tanaka; Kinzo Ueda; Takashi Akasaka; Keiichi Igarashi Hanaoka; Shiro Uemura; Hirotaka Oda; Yoshiaki Katahira; Kazushige Kadota; Eisho Kyo; Katsuhiko Sato; Tadaya Sato; Junya Shite; Koichi Nakao; Masami Nishino; Yutaka Hikichi; Junko Honye; Tetsuo Matsubara; Sumio Mizuno; Toshiya Muramatsu; Taku Inohara; Shun Kohsaka; Ichiro Michishita; Hiroyoshi Yokoi; Patrick W Serruys; Yuji Ikari; Masato Nakamura
Journal:  Cardiovasc Interv Ther       Date:  2018-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.